A
Alto Neuroscience, Inc. (ANRO)
NYQ – Real Time Price. Currency in USD
20.50
-0.32 (-1.54%)
At close: Mar 27, 2026, 4:00 PM EDT
20.93
+0.43 (2.10%)
After-hours: Mar 27, 2026, 6:16 PM EDT
Get all premium features to the best stock analysis tool
NYQ – Real Time Price. Currency in USD
20.50
-0.32 (-1.54%)
At close: Mar 27, 2026, 4:00 PM EDT
20.93
+0.43 (2.10%)
After-hours: Mar 27, 2026, 6:16 PM EDT
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company’s product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist for patients with Parkinson’s disease for patients with Parkinson’s disease. The company was incorporated in 2019 and is headquartered in Mountain View, California.
| Name | Position |
|---|---|
| Dr. Amit Etkin M.D., Ph.D. | Founder, Chairman of the Board, CEO & President |
| Mr. Adam Savitz M.D., Ph.D. | Chief Medical Officer |
| Mr. Dan Segal B.Sc. (Hons), BCom, CA, MSc | Co-Founder & Strategic Advisor |
| Mr. Michael C. Hanley M.B.A. | Chief Operating Officer |
| Mr. Nicholas C. Smith | CFO & Chief Business Officer |
| Ms. Erin R. McQuade J.D. | General Counsel, Chief Administrative Officer & Corporate Secretary |
| Ms. Jessica Powell | Chief Development Officer |
| Date | Type | Document |
|---|---|---|
| 2026-03-16 | 8-K | alto-20260316.htm |
| 2025-11-28 | S-3 | tm2531771-1_s3.htm |
| 2025-11-12 | 10-Q | alto-20250930.htm |
| 2025-10-27 | D | |
| 2025-10-20 | 8-K | tm2529007d1_8k.htm |
| 2025-08-13 | 10-Q | alto-20250630.htm |
| 2025-07-08 | 8-K | alto-20250703.htm |
| 2025-06-26 | 8-K | alto-20250626.htm |
| 2025-06-03 | 8-K | alto-20250531.htm |
| 2025-05-14 | 8-K | alto-20250513.htm |